Lineage Cell Therapeutics (LCTX) Cash from Financing Activities (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Cash from Financing Activities of $5.6 million for Q1 2026, up 10.25% year-over-year from $5.0 million in Q1 2025, and down 72.71% quarter-over-quarter from $20.4 million in Q4 2025.
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $5.6 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 10.25% year-over-year to $5.6 million; the TTM figure through Mar 2026 stood at $27.5 million (up 2.18% YoY), while the FY2025 annual figure was $27.0 million, down 24.84% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $5.6 million, down from $20.4 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $21.7 million in Q4 2024, with the low at -$307000.0 in Q2 2025.
- The 5-year median for Cash from Financing Activities is $807000.0 (2023), against an average of $4.5 million.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities soared 1402000.0% in 2024, then sank 392.38% in 2025.
- Lineage Cell Therapeutics' Cash from Financing Activities stood at $122000.0 in 2022, then sank by 110.66% to -$13000.0 in 2023, then surged by 167284.62% to $21.7 million in 2024, then decreased by 6.23% to $20.4 million in 2025, then tumbled by 72.71% to $5.6 million in 2026.
- Business Quant data shows LCTX's Cash from Financing Activities at $5.6 million in Q1 2026, $20.4 million in Q4 2025, and $1.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Lineage Cell Therapeutics | 270.71 Mn | 213.99 Mn | 1.07 Mn | 4.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.47 Mn |
| Mar 31, 2026 | 5.56 Mn |
| Dec 31, 2025 | 20.38 Mn |
| Sep 30, 2025 | 1.83 Mn |
| Jun 30, 2025 | -307,000.00 |
| Mar 31, 2025 | 5.04 Mn |
| Dec 31, 2024 | 21.73 Mn |
| Sep 30, 2024 | -3,000.00 |
| Jun 30, 2024 | 105,000.00 |
| Mar 31, 2024 | 14.02 Mn |
| Dec 31, 2023 | -13,000.00 |
| Sep 30, 2023 | 807,000.00 |
| Jun 30, 2023 | 5.63 Mn |
| Mar 31, 2023 | 1,000.00 |
| Dec 31, 2022 | 122,000.00 |
| Sep 30, 2022 | 964,000.00 |
| Jun 30, 2022 | 33,000.00 |
| Mar 31, 2022 | 513,000.00 |
| Dec 31, 2021 | 954,000.00 |
| Sep 30, 2021 | 3.72 Mn |